Skip to NavigationSkip to content


Top Ten most popular articles on this week

With the UK in the grip of a record-breaking heatwave, it's hard to focus on much else over here, but it's been another packed week in the pharma industry.

The Brexit farce continues as the UK Government has admitted that the NHS will need to stockpile medicines in the event no deal can be reached with the EU on an exit deal, and Roche and AstraZeneca have followed in Pfizer's footsteps with pledges to pause price hikes until 2019, after the latter firm was chastised over social media by President Donald Trump.

But the most-read story this week is the heart-breaking news th

Top Ten most popular articles on this week

Summer seems to be in full swing as we reach the end of June, so it's time to look back on the most popular articles over the past week.

It was a week dominated with new drug approvals, particularly in the UK and Europe, in a range of indications including HIV, multiple sclerosis and lung cancer, while J&J's second most senior executive announces she is to leave the firm.

Amgen biosimilar proves non-inferior to J&J's Remicade in rheumatoid arthritis

Amgen has unveiled new Phase 3 data for its biosimilar version of Johnson & Johnson’s Remicade (infliximab), confirming that it demonstrated non-inferiority compared to its reference product in the treatment of moderate-to-severe rheumatoid arthritis.

Novartis' Sandoz scores EU approval for Remicade biosimilar

The European Commission has given its approval to Sandoz, Novartis’ generics and biosimilars unit, for its biosimilar version of Janssen’s Remicade (infliximab) and other products, known as Zessly.

The therapy has been authorised in all the indications of its reference product, which includes the treatment of rheumatoid arthritis, adult Crohn's disease, paediatric Crohn's disease, adult ulcerative colitis, paediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.

Top Ten most popular articles on this week

As we come to the end of January, it's Friday again - time for another rundown of the top ten most popular articles of this week.

GSK triumphed over rival firm Reckitt Benckiser in its legal battle, which saw the latter forced to withdraw its "misleading" advertising campaign trashing Glaxo's panadeine product, while New York City's mayoral administration launched a massive $500 million lawsuit against big pharma over their role in the opioid crisis.

US court upholds ruling that J&J's Remicade patent is invalid

The US Court of Appeals for the Federal Circuit has judged that Johnson & Johnson’s patent for its best-selling arthritis drug Remicade (infliximab) is invalid, upholding a previous decision by the US Patent and Trademark Office (PTO) that the antibodies covered by the patent were already disclosed in an earlier patent.

What will Pfizer do with its second Remicade biosimilar?

Pfizer is now in the unusual position of owning two biosimilars to Johnson & Johnson’s Remicade, though one of these is in partnership with Celltrion.

The FDA approved its second biosimilar, Ixifi, but with it already heavily invested in the commercialisation of Inflectra, alongside Celltrion, the question remains about what Pfizer will choose to do with its second version?

Switching Crohn's patients to biosimilar Inflectra from Remicade is safe and effective, Pfizer says

Pfizer has released new data on its Crohn’s disease (CD) treatment Inflectra (infliximab CT-P13) which indicate that switching patients to the drug from Remicade (infliximab) is comparably safe and effective to treatment with Remicade alone over a 24-week period.

Trials comparing the two therapies lasted 54 weeks in total, and results from this complete period in biologic-naïve patients with active CD indicated “the long-term effectiveness of treatment with CT-P13”, the company said in a statement.

MSD under CMA investigation over unfair Remicade pricing

MSD is facing legal trouble after the Competition and Marketing Authority (CMA) alleged that the pharmaceutical firm had engaged in anti-competition practices by implementing an unfair discount scheme for one of its top drugs, Remicade (infliximab).

J&J launches lawsuit to block release of Remicade biosimilar

Samsung Bioepis gained approval to launch its biosimilar to Johnson & Johnson’s Remicade just last month, on 21 April, but faces a legal challenge from the same company. J&J is claiming patent infringement on three of the patents related to its product, as it attempts to delay the release of the biosimilar to market.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches